Quantum Biopharma (QNTM) Common Equity (2020 - 2025)
Quantum Biopharma's Common Equity history spans 6 years, with the latest figure at $5.1 million for Q4 2025.
- On a quarterly basis, Common Equity fell 51.13% to $5.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.1 million, a 51.13% decrease, with the full-year FY2025 number at $5.1 million, down 51.13% from a year prior.
- Common Equity hit $5.1 million in Q4 2025 for Quantum Biopharma, down from $7.5 million in the prior quarter.
- Over the last five years, Common Equity for QNTM hit a ceiling of $148.9 million in Q3 2024 and a floor of $2.0 million in Q2 2025.
- Historically, Common Equity has averaged $28.6 million across 5 years, with a median of $10.3 million in 2024.
- Biggest five-year swings in Common Equity: soared 49.09% in 2021 and later plummeted 94.96% in 2025.
- Tracing QNTM's Common Equity over 5 years: stood at $54.1 million in 2021, then tumbled by 43.58% to $30.5 million in 2022, then tumbled by 57.73% to $12.9 million in 2023, then fell by 19.13% to $10.4 million in 2024, then crashed by 51.13% to $5.1 million in 2025.
- Business Quant data shows Common Equity for QNTM at $5.1 million in Q4 2025, $7.5 million in Q3 2025, and $2.0 million in Q2 2025.